All Oncology News

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

The FDA approved the PARP inhibitor olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer.

Children with TP53 pathogenic variants were more likely to both develop acute lymphoblastic leukemia, as well as secondary cancers later on, according to a recent analysis.

TAS-102 improved overall survival compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC).

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.

Lecia V. Sequist, MD, reflects on the practice-changing osimertinib data, ongoing trials exploring combination regimens, and discusses the potential for immunotherapy in EGFR-positive NSCLC.

Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.

Martee L. Hensley, MD, discusses the role of MSI-H and dMMR testing in the management of endometrial cancer.

Ruben A. Mesa, MD, discusses the significance of the RESPONSE study for patients with polycythemia vera.

Jia Ruan, MD, PhD, discusses the pivotal analysis of the combination of lenalidomide plus rituximab, as well as the next steps for this regimen in the field of mantle cell lymphoma.

Daniel DeRemer, PharmD, assistant director of Clinical Therapeutics and Incubator, discusses patient education on oral chemotherapy.

Dan Klein, President and CEO of Patient Access Network Foundation, discusses payment assistance for patients with cancer.

David H. Ilson, MD, PhD, discusses practice-changing trials, the optimal available therapies, and how immunotherapy fits into the future treatment paradigm for gastric cancer.

John L. Marshall, MD, recaps some of the biggest CRC advancements of 2017, and explains what those successes mean for the treatment paradigm moving forward.

David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.

Jesper B. Andersen, MSc, PhD, discusses the findings of a study evaluating a single-gene dissection approach in patients with intrahepatic cholangiocarcinoma.

Michael Broderson, PharmD, Nebraska Cancer Specialists, discusses the management of patients with cancer.

Karen Kellogg, PharmD, Cardinal Health, discusses the important role that the oncologist plays in dispensing.

The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.

Christopher Crane, MD, discusses modern innovative techniques in GI cancers.

Erminia Massarelli, MD, PhD, discusses the evolving paradigm of ALK-positive non-small cell lung cancer based on recent regulatory decisions and what additional advancements are expected in the year ahead.

Eileen O’Reilly, MD, discusses novel therapeutic approaches for the treatment of patients with pancreatic cancer.

Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.

Neal Dave, PharmD, Texas Oncology, discusses the role of positive quality interventions (PQI).

Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.

Randy Burkholder, vice president, Policy & Research, PhRMA, discusses the role that providers play in policy reform.

Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.

Providers using iKnowMed certified EHR technology are eligible for Quality Performance bonus points under Merit-based Incentive Payment System.